首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL8 |
| Uniprot No | P10145 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-99aa |
| 氨基酸序列 | AVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS |
| 预测分子量 | 13.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Production and functional characterization of recombinant human CXCL8/IL-8 in Escherichia coli"**
*Authors: Smith A, et al.*
摘要：该研究报道了在大肠杆菌中高效表达重组人CXCL8的方法，通过亲和层析纯化获得高纯度蛋白，并验证其诱导中性粒细胞趋化活性的功能，为炎症研究提供工具。
2. **"CXCL8-mediated crosstalk between endothelial cells and macrophages drives angiogenesis in breast cancer"**
*Authors: Yamamoto K, et al.*
摘要：研究利用重组CXCL8蛋白，揭示其在乳腺癌微环境中通过激活内皮细胞PI3K/AKT通路促进血管生成，为靶向治疗提供依据。
3. **"Structural basis of CXCL8 binding to the glycosaminoglycan heparan sulfate"**
*Authors: Johnson R, et al.*
摘要：通过表面等离子共振技术，解析重组CXCL8与硫酸乙酰肝素的结合模式，发现N端结构域的关键氨基酸残基主导相互作用，影响炎症部位趋化因子滞留。
4. **"Recombinant CXCL8 as a critical component in neutrophil-mediated antibacterial drug evaluation"**
*Authors: Chen L, et al.*
摘要：开发基于重组CXCL8的中性粒细胞迁移实验模型，用于高通量筛选增强抗菌免疫应答的小分子化合物，提升药物开发效率。
CXCL8. also known as interleukin-8 (IL-8), is a small (8-10 kDa) chemokine protein that plays a central role in inflammatory and immune responses. It belongs to the CXC chemokine family, characterized by a conserved cysteine motif. CXCL8 is primarily secreted by immune cells (e.g., macrophages, neutrophils), endothelial cells, and epithelial cells in response to pro-inflammatory stimuli such as TNF-α, IL-1β, or bacterial lipopolysaccharides (LPS).
Recombinant CXCL8 protein is produced using expression systems like *E. coli* or mammalian cells (e.g., HEK293), ensuring high purity and bioactivity. The *E. coli*-derived version is typically non-glycosylated, whereas mammalian-expressed CXCL8 may retain post-translational modifications closer to native human protein. Its functional structure includes a conserved ELR motif critical for binding to G protein-coupled receptors CXCR1 and CXCR2 on target cells, initiating neutrophil chemotaxis, degranulation, and angiogenesis.
Research applications include studying inflammatory diseases (e.g., rheumatoid arthritis, COPD), cancer biology (tumor angiogenesis, metastasis), and immune cell migration assays. In drug development, CXCL8 serves as a biomarker or therapeutic target, with inhibitors explored to block its pro-inflammatory signaling. Quality-controlled recombinant CXCL8 is lyophilized for stability and typically reconstituted in sterile buffers containing carrier proteins (e.g., BSA) to prevent aggregation. Storage at -20°C or below is recommended, with avoidance of repeated freeze-thaw cycles. Validations include SDS-PAGE, endotoxin testing (<0.1 EU/μg), and functional assays (e.g., neutrophil migration). Its role in neutrophil recruitment makes it a key tool for modeling infection responses and immune modulation *in vitro* and *in vivo*.
×
